Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

NCT07686263 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

472

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Xanomeline/Trospium Chloride
DRUG: Placebo

Sponsor

Karuna Therapeutics, Inc., a Bristol Myers Squibb company